Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Time-Restricted Eating and Personalized Energy-Restricted Diet in Obese Postmenopausal Women

6 novembre 2026 aggiornato da: Aziz KILINC, Gazi University

Effects of Time-Restricted Eating and Personalized Energy-Restricted Diet on Menopause Symptoms, Sleep Quality, and Nutritional Status in Obese Postmenopausal Women

This clinical study aims to compare the effects of time-restricted eating and a personalized energy-restricted diet on anthropometric measurements, body composition, biochemical parameters, blood pressure, handgrip strength, menopausal symptoms, and sleep quality in obese postmenopausal women. The study is a 12-week, open-label, controlled, parallel-group clinical trial with a quasi-randomized allocation design. The coordinating center is the Department of Internal Medicine, Faculty of Medicine, Gazi University, and the study will be conducted at the Internal Medicine Outpatient Clinic of Cihanbeyli State Hospital in Konya, Türkiye.

A total of 40 postmenopausal women are planned to participate, with 20 participants in each group. Participants will undergo an initial medical examination and baseline assessments, including demographic and health information, dietary habits, menopausal symptoms, sleep quality, physical activity, and dietary intake. Anthropometric measurements, body composition, handgrip strength, blood pressure, and biochemical parameters will also be assessed.

Participants in the intervention group will follow a time-restricted eating schedule in which they will consume food within an 8-hour daily eating window and fast for 16 hours. The eating window will begin between 8:00 AM and 12:00 PM and will be determined by the participant. During the fasting period, water, unsweetened tea, plain coffee, and plain mineral water will be permitted. Participants in the control group will follow a personalized energy-restricted diet providing approximately 25% less energy than their estimated energy requirements. The diet will be planned according to menopausal nutrition recommendations and individual preferences.

Dietary intake will be monitored every 2 weeks. Anthropometric measurements, blood pressure, and handgrip strength will be assessed every 4 weeks. All baseline assessments will be repeated after the 12-week intervention period. The study hypothesis is that time-restricted eating will result in greater improvements than the personalized energy-restricted diet in anthropometric measurements and body composition, biochemical parameters, blood pressure, handgrip strength, menopausal symptoms, and sleep quality in obese postmenopausal women.

Panoramica dello studio

Descrizione dettagliata

Study Setting, Timing, and Sample

This study is a quasi-randomized, controlled, open-label, parallel-group intervention study. The coordinating center is the Department of Internal Medicine, Faculty of Medicine, Gazi University, and the study will be conducted among postmenopausal women attending the Internal Medicine Outpatient Clinic of Cihanbeyli State Hospital in Konya, Türkiye, who meet the eligibility criteria and agree to participate in the study.

The study will compare the effects of time-restricted eating and a personalized energy-restricted diet on anthropometric measurements, body composition, handgrip strength, blood pressure, biochemical parameters, sleep quality, and menopausal symptoms.

The sample size was determined based on changes in body weight reported in studies evaluating a personalized energy-restricted diet and time-restricted eating in postmenopausal women. Based on these values, the calculated effect size was Cohen's d = 1.13. A power analysis was performed using G*Power 3.1.9.7 based on a two-tailed independent-samples t-test. With an alpha level of 0.05, statistical power of 0.85, and an effect size of 1.13, a minimum of 16 participants per group, corresponding to 32 participants in total, was required to achieve adequate statistical power (actual power = 0.85). Considering an anticipated 20% participant loss, a total of 40 participants, with 20 participants in each group, will be recruited.

Participant recruitment is planned between November 1, 2026 and August 1, 2027.

Eligible individuals will be informed in detail about the study, and written informed consent will be obtained from those who agree to participate.

Study Design and Group Allocation

The study is designed as a quasi-randomized, controlled, open-label, parallel-group intervention study. Participants will be stratified according to age (<55 and ≥55 years) and body mass index (BMI; <35 and ≥35 kg/m²), and stratified blocks will be created. Within these strata, a web-based randomization program (Random.org) will be used to determine the initial allocation of participants to the intervention or control group.

The stratified blocks will be created to minimize potential differences in age and BMI between the intervention and control groups.

After the allocation is communicated, participants who do not wish to follow the assigned dietary intervention may request participation in the other dietary group. Such requests may be accommodated depending on the number of participants in each group. If the requested change cannot be accommodated because of group size limitations, the participant will be withdrawn from the study.

Because of the nature of the dietary interventions, neither the participants nor the researchers can be blinded to group assignment.

General Study Plan

The study consists of an initial assessment and a 12-week intervention period.

Initial Assessment and Pre-Visit Conditions

Before the intervention, participants will undergo a comprehensive baseline assessment. Height, body weight, waist circumference, and hip circumference will be measured, and BMI and waist-to-height ratio will be calculated.

Body composition, including fat-free mass, fat mass, muscle mass, and body water, will be assessed using a Tanita DC 360 bioelectrical impedance analysis device.

Nutritional status will be assessed using a 3-day dietary record, including two weekdays and one weekend day. Physical activity level will be assessed using two 24-hour physical activity records, including one weekday and one weekend day.

Handgrip strength will be measured using an electronic hand dynamometer. Blood pressure will be measured, and fasting venous blood samples will be collected for biochemical analyses. Menopausal symptoms will be assessed using the Menopause Rating Scale, and sleep quality will be assessed using the Pittsburgh Sleep Quality Index.

Participants will be instructed regarding the conditions required before measurements. For biochemical analyses, blood samples will be collected in the morning after at least 10 hours of fasting. Participants who do not meet the required fasting conditions will be asked to attend the study site in the morning after completing the required fasting period without consuming food or beverages.

Intervention Group: Time-Restricted Eating

Participants assigned to the intervention group will receive general healthy eating recommendations for the postmenopausal period and will be instructed to follow a time-restricted eating schedule for 12 weeks. Participants will consume food within an 8-hour daily eating window and fast for 16 hours.

The starting time of the eating window will be selected by the participant between 08:00 and 12:00. During the 16-hour fasting period, water, unsweetened tea, plain coffee, and plain mineral water will be permitted.

No additional energy restriction will be prescribed in the time-restricted eating group.

Control Group: Personalized Energy-Restricted Diet

Participants assigned to the control group will receive general healthy eating recommendations for the postmenopausal period and will follow a personalized energy-restricted diet for 12 weeks. The diet will be planned in accordance with the dietary recommendations provided in the guidelines of national and international menopause societies, while also considering individual dietary preferences.

Energy requirements will be estimated using the Mifflin-St Jeor equation, and the prescribed diet will provide approximately 25% less energy than the estimated daily energy requirement.

Participants will be advised to consume three main meals, consisting of breakfast between 08:00 and 10:00, lunch between 12:00 and 13:00, and dinner between 18:00 and 19:00, with one to three snacks according to individual needs.

Follow-up and Monitoring

Dietary adherence and dietary intake will be monitored every 2 weeks using dietary records. Participants will be invited to the Dietitian Clinic of Cihanbeyli State Hospital for follow-up.

Anthropometric measurements, blood pressure, and handgrip strength will be assessed every 4 weeks during the intervention. Thus, these measurements will be performed at baseline and at weeks 4, 8, and 12.

At the end of the 12-week intervention, baseline assessments will be repeated. Menopausal symptoms and sleep quality will be reassessed during the study, whereas diet satisfaction will be assessed once at the end of the study. A 3-day dietary record and two 24-hour physical activity records will be obtained, and anthropometric measurements, body composition, handgrip strength, blood pressure, and biochemical parameters will be reassessed.

Anthropometric Measurements

Anthropometric measurements will be performed by the study dietitian.

Body weight: Body weight will be measured barefoot and wearing light clothing using a Tanita DC 360 body composition analyzer.

Height: Height will be measured using a F. BOSCH wall-mounted stadiometer, with the participant standing with the feet together and the head positioned in the Frankfurt horizontal plane.

Body mass index: BMI will be calculated as body weight in kilograms divided by height in meters squared and will be evaluated according to WHO criteria.

Waist circumference: Waist circumference will be measured in centimeters at the midpoint between the lowest rib and the iliac crest using a non-stretchable, flexible fiberglass measuring tape.

Hip circumference: Hip circumference will be measured at the widest point of the hips using a non-stretchable, flexible fiberglass measuring tape.

Waist-to-height ratio: Waist-to-height ratio will be calculated by dividing waist circumference by height and will be evaluated according to the Ashwell classification.

Waist-to-hip ratio: Waist-to-hip ratio will be calculated by dividing waist circumference by hip circumference.

Assessment of Body Composition

Body composition will be assessed by the study dietitian using a Tanita DC 360 bioelectrical impedance analysis device. Fat-free mass, fat mass, muscle mass, body water, and visceral fat level will be obtained.

Measurements will be performed in the morning under standardized conditions. Participants will be instructed to avoid strenuous physical activity for 48 hours before the measurement, refrain from eating for at least 4 hours before the test, avoid excessive fluid intake before the measurement, avoid tea and coffee for 4 hours before the measurement, and remove metal objects that may come into contact with the body during the assessment.

Handgrip Strength

Handgrip strength will be measured by the study dietitian using an electronic hand dynamometer (DEMPOWER DP434). One measurement will be obtained from each hand, and the mean of the two measurements will be used for analysis. Handgrip strength below 16 kg will be classified as low muscle strength.

Assessment of Dietary Intake

Nutritional intake will initially be assessed using a 3-day dietary record consisting of two weekdays and one weekend day. Reported food and beverage quantities will be converted into standard amounts by the researcher. Energy, macronutrient, and micronutrient intakes will be analyzed using the Computer-Assisted Nutrition Program, Nutrition Information Systems Package Program (BEBIS).

Dietary intake will be monitored every 2 weeks during the intervention to assess dietary adherence.

Assessment of Physical Activity

Physical activity will be assessed using two 24-hour physical activity records, consisting of one weekday and one weekend day. The duration of sleep, lying, sedentary activities, and light, moderate, and vigorous activities during a 24-hour period will be recorded.

Total energy expenditure will be calculated by multiplying the duration of each activity by the corresponding physical activity ratio (PAR). Physical activity level (PAL) will be calculated by dividing total energy expenditure by 24 hours.

Assessment of Menopausal Symptoms

Menopausal symptoms will be assessed using the Turkish version of the Menopause Rating Scale, for which validity and reliability have been established. The scale consists of 11 items and the total score ranges from 0 to 44. Higher scores indicate greater severity of menopausal symptoms.

Assessment of Sleep Quality

Sleep quality will be assessed using the Turkish version of the Pittsburgh Sleep Quality Index, for which validity and reliability have been established. The total score ranges from 0 to 21, with a score ≤5 indicating good sleep quality.

Assessment of Diet Satisfaction

Diet satisfaction will be assessed at the end of the intervention using the Diet Satisfaction Scale. The Turkish version of the scale has established validity and reliability. The scale consists of 9 items and uses Likert-type scoring. The maximum possible score is 45, with higher scores indicating greater diet satisfaction.

Blood Pressure Measurement

Blood pressure will be measured by the study nurse. Systolic and diastolic blood pressure (mmHg) and heart rate (beats/minute) will be measured using an automatic oscillometric blood pressure monitor (OMRON M2 Basic), with the participant seated and the measurement taken once from the right arm.

Before measurement, participants will be asked about recent exercise, food intake, medication use, and tea or coffee consumption. Participants will rest for at least 5 minutes before blood pressure measurement.

Biochemical Assessments

Venous blood samples will be collected from all participants at baseline (week 0) and at the end of the intervention (week 12), following at least 10 hours of fasting. Blood samples will be collected by the study nurse in the morning, and all biochemical analyses will be performed in the laboratory of Cihanbeyli State Hospital.

The following parameters will be analyzed: fasting blood glucose (mg/dL), fasting insulin (mIU/L), HbA1c (%), total cholesterol (mg/dL), HDL cholesterol (mg/dL), LDL cholesterol (mg/dL), triglycerides (mg/dL), alanine aminotransferase (ALT; U/L), aspartate aminotransferase (AST; U/L), ferritin (ng/mL), 25-hydroxyvitamin D (ng/mL), vitamin B12 (ng/L), C-reactive protein (CRP; mg/L), neutrophil-to-lymphocyte ratio, and thyroid-stimulating hormone (TSH; mIU/L).

Tipo di studio

Interventistico

Iscrizione (Stimato)

40

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Cihanbeyli
      • Konya, Cihanbeyli, Turchia (Türkiye), 42850
        • Reclutamento
        • Cihanbeyli State Hospital
        • Contatto:
          • Aziz Kılınç, MSc
          • Numero di telefono: +90 541-766-1850
        • Contatto:
          • Numero di telefono: +90541-766-1850

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 50 anni a 60 anni (Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Descrizione

Inclusion Criteria:

  • Aged 50-60 years
  • Body mass index (BMI) ≥30 and ≤40 kg/m²
  • No menstrual periods for at least 1 year
  • No history of hypoglycemia
  • No special diet during the previous 3 months and stable body weight (within ±3 kg)
  • Usual daily eating window of ≥10 hours

Exclusion Criteria:

  • Surgical menopause
  • Current use of hormone replacement therapy
  • Current use of lipid-lowering, glucose-lowering, antihypertensive, corticosteroid, or anticoagulant medications
  • Current use of weight-loss medications (e.g., orlistat, liraglutide) or diuretics
  • Diagnosis of cancer within the previous 5 years
  • Kidney disease, liver disease (except fatty liver disease), heart failure, type 1 or type 2 diabetes mellitus, or uncontrolled hypertension
  • Severe psychiatric disorders (e.g., anxiety disorder or schizophrenia)
  • Active metabolic bone diseases (e.g., Paget disease or osteomalacia)
  • Diagnosis of an eating disorder
  • Current treatment for a sleep disorder
  • Current smoking and/or alcohol use
  • Working night shifts (between 11:00 PM and 6:00 AM)
  • Conditions requiring a special diet, such as celiac disease

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Time-Restricted Eating Group

Participants will follow a time-restricted eating schedule for 12 weeks, consuming food within an 8-hour daily eating window and fasting for 16 hours. The starting time of the eating window will be selected by the participant between 08:00 and 12:00. During the fasting period, water, unsweetened tea, plain coffee, and plain mineral water will be permitted. No additional energy restriction will be prescribed.

Participants will consume food within an 8-hour daily eating window and fast for 16 hours for 12 weeks. The starting time of the eating window will be selected by the participant between 08:00 and 12:00. During the fasting period, water, unsweetened tea, plain coffee, and plain mineral water will be permitted. No additional energy restriction will be prescribed.

Comparatore attivo: Personalized Energy-Restricted Diet Group

Participants will follow a personalized energy-restricted diet for 12 weeks, providing approximately 25% less energy than their estimated daily energy requirement. The diet will be planned according to dietary recommendations provided in the guidelines of national and international menopause societies and individual dietary preferences.

Participants will follow a personalized energy-restricted diet for 12 weeks, providing approximately 25% less energy than their estimated daily energy requirement. The diet will be planned according to dietary recommendations provided in the guidelines of national and international menopause societies and individual dietary preferences.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in body weight
Lasso di tempo: Baseline to Week 12

Change in body weight from baseline to week 12, measured in kilograms (kg). Body weight will be measured at baseline and at weeks 4, 8, and 12 during the intervention.

Baseline to Week 12
Change in menopausal symptoms
Lasso di tempo: Baseline to Week 12

Change in menopausal symptom severity assessed using the Menopause Rating Scale. The total score ranges from 0 to 44, with higher scores indicating more severe menopausal symptoms and a worse outcome.

Baseline to Week 12
Change in sleep quality
Lasso di tempo: Baseline to Week 12

Change in sleep quality assessed using the Pittsburgh Sleep Quality Index. The total score ranges from 0 to 21, with higher scores indicating poorer sleep quality.

Baseline to Week 12

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in total cholesterol
Lasso di tempo: Baseline to Week 12
Baseline to Week 12
Change in systolic blood pressure
Lasso di tempo: Baseline to Week 12
Baseline to Week 12
Change in diastolic blood pressure
Lasso di tempo: Baseline to Week 12
Baseline to Week 12
Change in waist circumference
Lasso di tempo: Baseline to Week 12
Baseline to Week 12
Change in fat mass
Lasso di tempo: Baseline to Week 12

Change in fat mass measured by bioelectrical impedance analysis using the Tanita DC 360, expressed in kilograms, and %.

Baseline to Week 12
Change in fat-free mass
Lasso di tempo: Baseline to Week 12

Change in fat-free mass measured by bioelectrical impedance analysis using the Tanita DC 360, expressed in kilograms, and %.

Baseline to Week 12
Change in body water
Lasso di tempo: Baseline to Week 12

Change in body water measured by bioelectrical impedance analysis using the Tanita DC 360, expressed in kilograms, and %.

Baseline to Week 12
Change in visceral fat level
Lasso di tempo: Baseline to Week 12

Change in visceral fat level measured by bioelectrical impedance analysis using the Tanita DC 360.

Baseline to Week 12
Change in body mass index (BMI)
Lasso di tempo: Baseline to Week 12

BMI is calculated as body weight in kilograms divided by the square of height in meters (kg/m²).

Baseline to Week 12
Change in hip circumference
Lasso di tempo: Baseline to Week 12
Baseline to Week 12
Change in waist-to-height ratio
Lasso di tempo: Baseline to Week 12
Baseline to Week 12
Change in waist-to-hip ratio
Lasso di tempo: Baseline to Week 12
Baseline to Week 12
Change in handgrip strength
Lasso di tempo: Baseline to Week 12
Baseline to Week 12
Change in fasting blood glucose
Lasso di tempo: Baseline to Week 12
Baseline to Week 12
Change in fasting insulin
Lasso di tempo: Baseline to Week 12
Baseline to Week 12
Change in Glycated hemoglobin (HbA1c)
Lasso di tempo: Baseline to Week 12
Baseline to Week 12
Change in High-density lipoprotein cholesterol (HDL-C)
Lasso di tempo: Baseline to Week 12
Baseline to Week 12
Change in Low-density lipoprotein cholesterol (LDL-C)
Lasso di tempo: Baseline to Week 12
Baseline to Week 12
Change in triglycerides
Lasso di tempo: Baseline to Week 12
Baseline to Week 12
Change in Alanine aminotransferase (ALT)
Lasso di tempo: Baseline to Week 12
Baseline to Week 12
Change in Aspartate aminotransferase (AST)
Lasso di tempo: Baseline to Week 12
Baseline to Week 12
Change in ferritin
Lasso di tempo: Baseline to Week 12
Baseline to Week 12
Change in 25-hydroxyvitamin D
Lasso di tempo: Baseline to Week 12
Baseline to Week 12
Change in vitamin B12
Lasso di tempo: Baseline to Week 12
Baseline to Week 12
Change in C-reactive protein
Lasso di tempo: Baseline to Week 12
Baseline to Week 12
Change in neutrophil-to-lymphocyte ratio
Lasso di tempo: Baseline to Week 12
Baseline to Week 12
Change in thyroid-stimulating hormone
Lasso di tempo: Baseline to Week 12
Baseline to Week 12
Change in Framingham Risk Score
Lasso di tempo: Baseline to Week 12

The score estimates the 10-year risk of developing cardiovascular disease and is expressed as a percentage (%). Possible values range from 0% to 100%, with higher values indicating a higher cardiovascular risk and a worse outcome. Change will be calculated as the value at the end of the intervention minus the baseline value.

Baseline to Week 12
Change in Lipid Accumulation Product
Lasso di tempo: Baseline to Week 12

Lipid Accumulation Product is a sex-specific index calculated using waist circumference and fasting triglyceride concentration. Change will be calculated as the Lipid Accumulation Product value at the end of the intervention minus the baseline Lipid Accumulation Product value. Higher Lipid Accumulation Product values indicate greater lipid accumulation and are generally associated with increased cardiometabolic risk, representing a worse outcome.

Baseline to Week 12
Change in visceral adiposity index
Lasso di tempo: Baseline to Week 12

Visceral Adiposity Index is a sex-specific index calculated using waist circumference, body mass index, fasting triglyceride concentration, and high-density lipoprotein cholesterol concentration. Change will be calculated as the Visceral Adiposity Index value at the end of the intervention minus the baseline value. Higher Visceral Adiposity Index values generally indicate greater visceral adipose tissue dysfunction and are associated with increased cardiometabolic risk, representing a worse outcome.

Baseline to Week 12

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 novembre 2026

Completamento primario (Stimato)

24 ottobre 2027

Completamento dello studio (Stimato)

31 ottobre 2027

Date di iscrizione allo studio

Primo inviato

8 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

8 ottobre 2026

Primo Inserito (Effettivo)

14 ottobre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

6 novembre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual participant data will not be shared with other researchers because no data-sharing plan has been established for this study.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi